Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
Abstract Background Telavancin—a lipoglycopeptide antibacterial agent active against Gram-positive pathogens including methicillin-sensitive and -resistant Staphylococcus aureus (MRSA)—is approved in the USA for once-daily intravenous use. This registry study captured patient characteristics, prescr...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Adis, Springer Healthcare
2019-11-01
|
| Серии: | Drugs - Real World Outcomes |
| Online-ссылка: | http://link.springer.com/article/10.1007/s40801-019-00165-8 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|